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Abstract: The pathogenic bacterium Shigella flexneri is a leading global cause of diarrheal
disease. The O-antigen is the primary vaccine target and distinguishes the 30 serotypes reported.
Except for serotype 6, all S. flexneri serotypes have a common backbone repeating unit (serotype Y),
with variations in substitution creating the various serotypes. A quadrivalent vaccine containing
serotypes 2a and 3a (as well as 6 and Shigella sonnei) is proposed to provide broad protection against
non-vaccine S. flexneri serotypes through shared epitopes and conformations. Here we model the
O-antigen (O-Ag) conformations of serogroups 3 and 5: a continuation of our ongoing systematic
study of the S. flexneri O-antigens that began with serogroup 2. Our simulations show that S. flexneri
serogroups 2, 3, and 5 all have flexible O-Ags, with substitutions of the backbone altering the chain
conformations in different ways. Our analysis suggests three general heuristics for the effects of
substitution on the Shigella O-Ag conformations: (1) substitution on rhamnose C reduces the extension
of the O-Ag chain; (2) substitution at O-3 of rhamnose A restricts the O-Ags to predominantly
helical conformations, (3) substitution at O-3 of rhamnose B has only a slight effect on conformation.
The common O-Ag conformations across serotypes identified in this work support the assumption
that a quadrivalent vaccine containing serotypes 2a and 3a could provide coverage against S. flexneri
serotype 3b and serogroup 5.
Keywords: O-antigen; conformation; Shigella flexneri; molecular modelling; cross protection
1. Introduction
Diarrheal diseases cause over 1.6 million deaths each year [1], disproportionately affecting
low-income regions [2] and young children [3]. Shigella flexneri is a leading cause of enteric infections,
with no licensed vaccine currently available [4]. The increasing prevalence of antibiotic resistant
strains [5–8] necessitates a broad coverage Shigella vaccine to prevent infection [4,9] and reduce the
global disease burden [10,11].
The structure of the S. flexneri O-antigen (O-Ag) repeating unit (RU)—the carbohydrate component
of the cell-surface lipopolysaccharide—classifies strains into approximately 30 serotypes and seven
serogroups [12,13]. The O-Ag is the primary target of the host immune response [14,15] and is a
focus of current vaccine development [16,17]. Except for serotype 6, all S. flexneri serotypes have
the same backbone RU-serotype Y: →2)-α-L-RhapIII-(1→2)-α-L-RhapII-(1→ 3)-α-L-RhapI-(1→3)-β-
D-GlcpNAc-(1→ (Figure 1a). Serotypes are defined by the combination of type O-factor epitopes in the
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O-Ag RU (which distinguish the serogroups from each other) as well as the group O-factors determined
by glucosylation, O-acetylation, and phosphorylation substitution of the serotype Y backbone,
which appear across serogroups [13,18]. The similarities between S. flexneri O-Ags (shared backbone
and group O-factors) suggest that some serotypes may cross-protect, enabling development of a
broad-coverage vaccine with minimal valency. The proposed vaccine for Shigella based on the
Global Enteric Multicenter Study (GEMS) consists of S. flexneri serotypes 2a, 3a, 6, and the single
S. sonnei serotype, which is estimated to provide direct protection against 64% of Shigella strains
causing infection in children in low-income areas, with cross-reactivity potentially extending this up
to 88% [19–21]. Serotypes 2a and 3a were chosen as vaccine components because both are prevalent
causes of infection (ranked 1st and 4th, respectively) and together they express the group O-factor
epitopes (group O-factors 6; 7,8; 9) found on most remaining non-vaccine serotypes, allowing for
potential broad cross-protection.
As cross-protection between antigens is expected to require both chemical and conformational
similarity [22], molecular modeling can provide insight into the potential for cross-protection between
S. flexneri O-Ags. Early computational models indicated an extended conformation for serotype
Y [23], and a helix for serotype 5a [24]. However, MD simulations predicted that serotype Y is highly
flexible [25,26] and that 3 RU of 12 S. flexneri O-Ags show similar conformations to each other [27,28].
Although S. flexneri expresses a heterogenous distribution of O-Ag chain lengths, 3 RU is considered
sufficient to represent the O-antigen conformation [17,27].
We previously embarked on a systematic conformational study of all the Shigella O-Ags,
beginning with the backbone (serotype Y) and the serogroup 2 O-Ags [26]. For the serotype 2a
O-Ag (Figure 1b), we found that glucosylation on O-4 of rhamnose C (type O-factor II) [13] restricted
the O-Ag to more compact conformations as compared to the highly flexible, unsubstituted serotype
Y. Additional substitution on O-3 of rhamnose A produced more extended helical conformations,
regardless of whether it was O-acetylation (serotype 2a, group O-factor 9) or glucosylation
(serotype 2b; group O-factor 7,8; Figure 1c). This work indicated that an O-3-acetylated 2a O-Ag
(expressing group O-factor 9) may provide stronger cross-protection against 2b (ranked 3rd in
prevalence, expressing group O-factor 7,8) than 2a (which lacks both O-factors) and may provide
enhanced coverage of other serotypes expressing O-factor 9 (serotypes Y1, 1a1, 1b, 5a1, 6, and 7a1) [13].
Here we report the next step of our study, modeling the conformations of serotypes 3a, 3b,
and serogroup 5. Serotype 3a is a component of the proposed quadrivalent vaccine [19,20] as it
is prevalent globally [19]. Serotype 3b is not included in the vaccine, but is prevalent in parts of
Asia [29,30]. In contrast, serogroup 5 has a relatively low incidence of disease; serotype 5a has been
widely studied and is used as a reference strain, whereas 5b accounted for some cases in the GEMS
report [19].
All serotypes in serogroup 3 contain O-acetylation on O-2 of rhamnose C (group O-factor 6) [13],
which is important for antibody recognition [31,32]. Serotype 3a (Figure 1d) is defined by additional
glucosylation on O-3 of rhamnose A (O-factor 7,8), with subtype 3a1 having partial O-acetylation on
O-6 of GlcNAc D (O-factor 10, ≈40%); neither of which are present in serotype 3b (Figure 1e) [12,13].
Serotype 5a (Figure 1f) is defined by glucosylation at position O-3 of rhamnose B (type O-factor V) with
subtype 5a1 having partial O-3-acetylation on rhamnose A (group O-factor 9, ≈35%) [13]. The most
common 5a strain for laboratory study (M90T) has no O-acetylation [33,34]. Serotype 5b (Figure 1g) is
glucosylated on O-3 of rhamnose A (O-factor 7,8) with no O-acetylation.
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Figure 1. Line structures and diagrams of the Shigella flexneri O-antigen repeating units of serotypes 
(a) Y, (b) 2a, (c) 2b, (d) 3a, (e) 3b, (f) 5a, and (g) 5b. All serogroups share the serotype Y backbone and 
are distinguished by substitutions, which are labelled with the associated O-factors. Vaccine 
serotypes 2a and 3a are indicated with an asterisk. Schematic diagrams are depicted using the 
Symbol Nomenclature for Glycans (SNFG) symbol set [35] where green triangle—Rha, blue 
square—GlcNAc, blue circle—Glc, red triangle—O-acetylation. 
Some studies have indicated cross-reactivity between serogroups 2, 3, and 5. Serotypes 2a, 3b, 
and 5a each react with group O-factor 3,4 antisera (associated backbone trisaccharide residues 
C-D-A) [12] and partial cross-reactivity with these strains is demonstrated from serotype 2a in 
human testing [36]. Serotypes 2b, 3a, and 5b share glucosylation on O-3 of rhamnose A (group 
O-factor 7,8) and strong cross-reactivity is reported from a candidate 2a/3a vaccine against 2b and 5b 
in guinea pigs [37]. Therefore, a vaccine containing serotypes 2a and 3a (expressing group O-factors 
6; 7,8 and 9) is suggested to elicit broad cross-protection against the remaining serogroup 2, 3, and 5 
serotypes [19]. 
Here we compare simulations of serogroups 3 and 5 with our recent work on the serogroup 2 
O-Ags, contrasting the O-Ag behavior for O-acetylated serotype 2a (group O-factor 9) and 3a (group 
O-factors 6 and 7,8) with the non-vaccine serotype 3b (group O-factor 6) as well as serotypes 5a (type 
O-factor V) and 5b (group O-factor 7,8). With this large data set for comparison, we aim to broadly 
identify guiding heuristics for the conformational effect of substitutions on particular positions of 
Figure 1. Line structures and diagrams of the Shigella flexneri O-antigen repeating units of serotypes (a)
Y, (b) 2a, (c) 2b, (d) 3a, (e) 3b, (f) 5a, and (g) 5b. All serogroups share the serotype Y backbone and are
distinguished by substitutions, which are labelled with the associated O-factors. Vaccine serotypes 2a
and 3a are indicated with an asterisk. Schematic diagrams are depicted using the Symbol Nomenclature
for Glycans (SNFG) symbol set [35] where green triangle—Rha, blue square—GlcNAc, blue circle—Glc,
red triangle—O-acetylation.
Some studies have indicated cross-reactivity between serogroups 2, 3, and 5. Serotypes 2a,
3b, and 5a each react with group O-factor 3,4 antisera (associated backbone trisaccharide residues
C-D-A) [12] and partial cross-reactivity with these strains is demonstrated from serotype 2a in human
testing [36]. Serotypes 2b, 3a, and 5b share glucosylation on O-3 of rhamnose A (group O-factor 7,8)
and strong cross-reactivity is reported from a candidate 2a/3a vaccine against 2b and 5b in guinea
pigs [37]. Therefore, a vaccine containing serotypes 2a and 3a (expressing group O-factors 6; 7,8 and 9)
is suggested to elicit broad cross-protection against the remaining serogroup 2, 3, and 5 serotypes [19].
Here we compare simulations of serogroups 3 and 5 with our recent work on the serogroup
2 O-Ags, contrasting the O-Ag behavior for O-acetylated serotype 2a (group O-factor 9) and 3a
(group O-factors 6 and 7,8) with the non-vaccine serotype 3b (group O-factor 6) as well as serotypes
5a (type O-factor V) and 5b (group O-factor 7,8). With this large data set for comparison, we aim
to broadly identify guiding heuristics for the conformational effect of substitutions on particular
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positions of the Shigella backbone, specifically substitutions on rhamnose C (O-factor II in serogroup
2 and O-factor 6 in serogroup 3); O-3 of rhamnose A (O-factor 9 in serotype 2a-3Ac; O-factor 7,8 in
serotypes 2b, 3a, and 5b); O-3 of rhamnose B (O-factor V in serogroup 5). We assume that O-factors
with a significant conformational effect should be represented in the vaccine serotypes to allow for
broad coverage. Ultimately, we aim to determine whether the conformational findings from our
computational modeling supports the assumption that a quadrivalent vaccine containing S. flexneri
serotypes 2a and 3a (as well as 6 and S. sonnei) could provide broad coverage against S. flexneri serotype
3b and serogroup 5.
2. Materials and Methods
The S. flexneri O-Ags have glycosidic linkages described by two dihedral angles, ϕ and ψ,
defined as ϕ = H1-C1-O1-Cx’ and ψ = C1-O1-Cx’-Hx’. These definitions are analogous to ϕH and ψH
in IUPAC nomenclature and are consistent with our previous carbohydrate modeling [26,38] This
work follows our established methodology for the computational study of carbohydrate antigens.
Potential of mean force (PMF) calculations for the disaccharide fragments of the O-Ag repeating unit
indicate the global minima for each linkage, which are then used to build short 3 RU chains for
initial 300 ns MD simulations in solution. The most populated linkage conformations from the 3 RU
simulations are then used to construct starting structures for the simulations of the 6 RU chains [39–41].
2.1. ϕ, ψ PMF Calculations
The low-energy conformations of the glycosidic linkages were determined by calculating the
potential of mean force (PMF) for rotation about the ϕ and ψ dihedral angles of each disaccharide
linkage. PMFs were calculated with the metadynamics algorithm [42] as implemented in NAMD [43].
The disaccharide PMFs were calculated in the gas-phase with the ϕ, ψ dihedral angles set as
collective variables.
2.2. Molecular Dynamics
Simulations were run with the NAMD software package [43], employing CUDA extensions
to leverage graphics processing units for the calculation of long-range electrostatic potentials and
non-bonded forces [44]. Carbohydrates were modelled with the CHARMM36 additive force field for
carbohydrates [45,46] and explicit water molecules were represented with the TIP3P water model [47].
Our in-house CarbBuilder software was used to build the carbohydrate structures prior to
simulation [48]. Initial 3 RU chains of the serogroup 3 and 5 O-Ags (not discussed here) were built
with glycosidic linkage conformations set to the energy minimum of the respective disaccharide PMFs.






The 3 RU simulations were run for 1000 and 300 ns (for serogroups 3 and 5, respectively), with the
most frequent dihedral angles from these simulations used to build the initial conformations for the 6
RU chains. These conformations were then subjected to 10,000 steps of standard NAMD minimization
in vacuum and subsequently placed into a cubic water box with the solvate command from the Visual
Molecular Dynamics (VMD) package [49]. The cubic water boxes for the 6 RU structures had side
lengths of 100 and 90 Å, respectively, for serogroups 3 and 5, and periodic boundary conditions were
employed. The solvated structures were gradually heated through a protocol of 5 K incremental
temperature reassignments between 10 and 310 K, with 1000 steps of NAMD minimization and 1000
steps of MD after each temperature reassignment.
Vaccines 2020, 8, 643 5 of 17
Equations of motion were integrated using the velocity-Verlet method [50] with a 1 fs step
size. Molecular dynamics simulations were performed under the isothermal-isobaric (nPT) ensemble
at a temperature of 310 K and maintained with a Langevin piston barostat [43] and Nose-Hoover
thermostat—a hybridized method of the Nose-Hoover constant pressure method [51] with piston
fluctuations controlled by Langevin dynamics [52], as implemented in NAMD. Particle mesh Ewald
(PME) summation [53] was used for calculation of long-range electrostatics, with k = 0.20 Å−1 and PME
grid dimensions that were set equal to the periodic cell size. Non-bonded interactions were truncated
at 15.0 Å and a switching function implemented between 12.0 and 15.0 Å. The 1–4 interactions were
not scaled, in accordance with CHARMM force field recommendations.
2.3. Block Averaging Analysis
Block averaging analysis is used to assess simulation convergence and is implemented with
in-house Python scripts [54]. The block averaging analysis algorithm splits a simulation trajectory with
N frames into a set of M “blocks” with a length of n frames, such that N = M × n. Next, an average of a
selected measurable (e.g., end-to-end distance) is calculated within each block. The block length (n)
is slowly increased and, at each value of n, the set of block averages are recalculated. The standard
deviation in the set of block averages, σn, is used to determine the blocked standard error (BSE) for
each value of n. The simulation is indicated to be converged once the running estimate of the BSE
asymptotes to a plateau, where the plateau represents the true standard error in the estimate of the
mean [55].
2.4. Data Analysis
Simulations underwent 200 ns of equilibration followed by production runs of 1 and 2 µs
(for serogroups 3 and 5, respectively). Snapshots of molecular conformations were taken at 25 ps
intervals from the simulation trajectories. Inter-atomic distances and dihedral angles were measured
from VMD’s Tcl console and graphical user interface, and statistical calculations were performed with
in-house Python scripts. For all saccharides, we defined the end-to-end distance, r, as the length from
C-2 of rhamnose B at the non-reducing end of the chain and C-1 of rhamnose C at the reducing end,
thus excluding the very flexible terminal sugar units.
Molecular conformations were visualized in VMD [49], with carbohydrate rings highlighted
by the PaperChain visualization algorithm [56]. Before conformational clustering, the trajectory
snapshots were aligned on the ring atoms of the central ‘C-D-A-B’ fragment between RU3 and
RU4—a frame-shifted full repeating unit to account for the variability in each linkage across the
different serotypes. The most common chain conformations are determined by clustering the simulation
snapshots into families with relative occupancies. We cluster the central 4 RU of each 6 RU chain, as the
terminal repeating units are less representative of the native O-Ag backbones. VMD’s internal cluster
command was employed to calculate the conformational clusters in the production runs with an RMSD
fit of the non-hydrogen atoms in the central 4 RUs with a cut-off of 5.5 Å. Clusters comprising less
than 5% of the simulation were excluded. The conformations of the previously published serotype Y
and serogroup 2 simulations [26] were recalculated under these criteria for a fair comparison between
the serogroups.
3. Results
We begin our analysis of the simulation data with a broad comparison of the O-Ag chain extension
and flexibility of S. flexneri serogroup 2 with serogroups 3 and 5; then we analyze the dominant
backbone conformation of each O-Ag; finally, we explore the conformational effects of the glucosylation
and O-acetylation on the orientations of the backbone glycosidic linkages.
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3.1. Simulation Convergence
We used block averaging analysis [54,55] of two metrics of chain flexibility—the end-to-end
distance, r, and the radius of gyration, Rg—to assess the convergence of the MD simulations.
Convergence is indicated by the plots of the blocked standard error (BSE) for both r and Rg (shown in
Figure S1a,b) reaching a plateau. The asymptote of the BSE plot represents the true standard error
in the measured variable, which can be used to approximate a correlation time for the simulation.
The range of correlation times from 18 to 104 ns indicate that the 200 ns equilibration period is
sufficient for all the O-Ags in this study. Further analysis reveals that the number of statistically
independent samples in each simulation is much greater than 1 (49, 58, 88, and 21 for 3a, 3b, 5a, and 5b,
respectively)—as recommended for a converged trajectory [55]. Therefore, block averaging analysis
indicates that the longer production runs (1000 ns for serogroup 3 and 2000 ns for serogroup 5) provide
sufficient sampling of the conformational space. The simulations of the more flexible serogroup 5
O-Ags were extended to 2 µs to ensure that convergence was achieved.
3.2. O-Ag Flexibility
The fluctuation in r over the course of a simulation is a simple measure of molecular extension
and flexibility for the S. flexneri O-Ags. Here we define r as the distance between C-2 of rhamnose B in
RU1 and C-1 of rhamnose C in RU6 (Figure 2a). Figure 2 compares the r time series and corresponding
histograms for the simulations of the serotype Y backbone and the serogroup 2 O-Ags previously
published [26] with simulations of serogroup 3 (Figure 2f,g) and serogroup 5 (Figure 2h,i).
For a first broad comparison of the O-Ags, a scan of the graphs in Figure 2 quickly reveals
that the unsubstituted Y backbone (Figure 2b) is by far the most flexible of the O-Ags, showing the
greatest range of r values (σ ≈ 16 Å), whereas the serogroup 2 O-Ags (Figure 2c–e) are the least flexible
(σ ≈ 8–9 Å). Serogroups 3 and 5 fall between these two extremes, with serogroup 3 being somewhat
less flexible (σ ≈ 13 Å for 3a, 14 Å for 3b) than serogroup 5 (σ ≈ 14 Å for 5a, 15 Å for 5b). Moreover,
the distributions of r vary considerably across the O-Ags. The flexible serogroup Y has a bimodal
distribution, in stark contrast to the well-defined tight distributions shown for serogroup 2.
The graphs of r reveal that the effect of glucosylation on the conformation and dynamics of the O-Ag
chain depends on the glucosylation position: compare the graph of serotype 2a expressing O-factor
II (O-4 glucosylation on rhamnose C, Figure 2c) with 5a expressing O-factor V (O-3 glucosylation
on rhamnose B, Figure 2h). In particular, the O-factor II glucosylation that defines serogroup 2 has
a very dramatic effect on r, reducing the overall extension and flexibility of the chain. In contrast,
the O-factor V glucosylation that defines serogroup 5 has a less obvious effect on r, slightly increasing
the average chain extension. Finally, O-factor 7,8 (O-3 glucosylation on rhamnose A; serotypes 2b,
3a, and 5b) appears to narrow the distribution of r, making the O-Ag chains more conformationally
defined. For example, there is a clear difference in the shape of the r distribution for serotype 3a
(Figure 2f) as compared to 3b (Figure 2g): serotype 3a has a unimodal distribution of r (mean 45 Å,
σ ≈ 13 Å) whereas in 3b (which lacks O-factor 7,8) r is shifted to smaller values and has a right-skewed
distribution with a peak at 25 Å (mean 29 Å, σ ≈ 14 Å). This significant shift in r distribution within
serogroup 3 indicates a substantial conformational difference between the 3a and 3b O-Ags, and hence
a significant conformational effect for O-factor 7,8. We have previously observed the same effect in
serogroup 2 and it can be observed within serogroup 5, which is the least conformationally defined of
the four serogroups. Serogroup 5 is the most similar to the Y backbone, but does not show the same
clear bimodal distribution. The r distributions for serotype 5b (expressing O-factor 7,8) show a slight
shift to more extended conformations (Figure 2i) as compared to 5a (Figure 2h). However, the similarity
of the r distributions for 5a and 5b suggest similar conformational behavior for both serotypes.
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Figure 2. Comparison of the r time series and corresponding histograms for 6 RU simulations of the
modeled S. flexneri O-Ags. (a) A 6 RU model of the serotype Y O-Ag depicted with the end-to-end
distance, r; rhamnose is colored pink and N-acetyl-glucosamine blue. The r time series (left column
for each serotype) and corresponding distribution (right column for each serotype) are shown for (b)
Y, (c) 2a, (d) O-3 acetylated 2a, (e) 2b, (f) 3a, (g) 3b, (h) 5a, and (i) 5b. The mean for each histogram
distribution is depicted with a dashed line and the corresponding standard deviation is indicated.
Further, a comparison of the r histograms can reveal the general effects of O-acetylation on the
O-Ag backbone. We have previously observed that O-factor 9 (O-acetylation at O-3 of rhamnose A,
serotype 2a-3Ac) has a similar conformational effect to glucosylation at this position (O-factor 7,8,
serotype 2b), reducing the range of r. The range restriction for O-acetylation is not as dramatic as
with glucosylation, which is expected from the relative size of the substituents (Ac = 43 g/mol and
Glc = 179 g/mol). More surprisingly, we now see that O-factor 6 (O-acetylation at O-2 of rhamnose C,
serogroup 3) has a similar effect restrictive effect on r, as can be seen in a comparison of serotype 3b
(Figure 2g) with the backbone serotype Y (Figure 2b).
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A general comparison of the r histograms suggests three broad heuristics for the effects of
substitution on the backbone (serotype Y) conformation of the Shigella O-Ags. First, substitution at
rhamnose C (O-factor II in serogroup 2 and O-factor 6 in serogroup 3) has the most impact in reducing
the flexibility and extension of the O-Ag chain, with glucosylation (2a) having a greater impact than
O-acetylation (3b). The impact of substitution on rhamnose C on O-Ag conformation is supported by
the fact that O-factor II defines serogroup 2 and O-factor 6 is present in all of serogroup 3. Second,
any substitution on O-3 of rhamnose A (O-factor 9 in serotype 2a-3Ac; O-factor 7,8 in serotypes 2b,
3a, and 5b) shifts the O-Ag to more extended conformations. Third, O-factor V (substitution at O-3
of rhamnose B, serogroup 5) does not have a significant effect on chain conformation. Our analysis
suggests that, at a first approximation, these three heuristics are additive. To test and refine these rules
of thumb, as well as investigate the potential for cross-reactivity between serotypes, we now perform a
detailed comparison of the chain conformations for all O-Ags.
3.3. O-Ag Conformations
Figure 3 compares the conformational families for serotype Y (Figure 3a) and the serogroup 2 O-Ags
(Figure 3b–d) with the serogroup 3 (Figure 3e,f) and serogroup 5 (Figure 3g,h) O-Ags. As discussed
in prior work [26], the flexible Y backbone transitions between extended conformations (Figure 3a
Y-1, Y-4, and Y-6) to more curved arrangements of the chain (Figure 3a Y-2, Y-3, and Y-5). Further,
we showed that O-factor II (O-4 glucosylation at rhamnose C, serogroup 2) has a dramatic effect on
the chain conformations, removing the extended conformations and restricting the O-Ag to a wide
range of “C-curves” (Figure 3b). Additional substitution on O-3 of rhamnose A, whether O-acetylation
in 2a (O-factor 9) or glucosylation in 2b (O-factor 7,8), was then shown to further restrict the chain
and induce helical conformations (compare Figure 3c,d). In common with serogroup 2, serogroup
3 is also substituted at rhamnose C, albeit with a smaller O-acetyl group at position 2 (O-factor 6).
A comparison of the dominant conformations of 2a (Figure 3b) and 3b (Figure 3f) reveals that O-factors
6 and II have a similar effect on the backbone. For the 3b O-Ag, O-2-acetylation on rhamnose C
removes most of the extended conformations of the chain and restricts the O-Ag to a range of C-curve
conformations (3b-1) and other folded conformations of the chain (3b-2, 3b-4 to 3b-7). The dominant
curved chain conformation for 2a (2a-1, 31%) and 3b (3b-1, 11%) are remarkably similar, indicating a
similar conformational effect of substitution at rhamnose C. However, the smaller O-acetyl substituent
means that the 3b chain remains more flexible than the 2a and has a minor helical conformational
family (3b-3, 7%).
As for serotype 2b, serotype 3a is substituted at rhamnose C as well as rhamnose A (O-factor 7,8).
This combination of substitutions has a similar effect on the conformation of the 3a O-Ag (Figure 3e)
as it does on 2b (Figure 3d), producing a dominant helical conformation with 3 RU per turn and an
average pitch of 29 Å (3a-1, 11%). However, 3a remains more flexible than 2b and can adopt a wide
range of helical conformations (3a-3, 3a-5), as well as partially extended chains (3a-2), fully extended
chains (3a-4), and S-bends (3a-6). Therefore, the serogroup 3 O-Ags follow a similar trend to serogroup
2 [26]: substitution on rhamnose C restricts the chains to curved conformations for both serotypes 2a
and 3b (Figure 3b,f) and additional substitution on O-3 of rhamnose A shifts the conformations towards
helices for serotypes 2a-3Ac, 2b, and 3a (Figure 3c–e). Further, the axially orientated O-acetyl groups of
serogroup 3 are readily accessible for antibody binding in both serogroup 3 O-Ags, which supports the
reported immunodominance of O-factor 6 [31].
A comparison of the primary conformations of serogroup 5 with the backbone shows the effect
of O-factor V (glucosylation at O-3 of rhamnose B) on the chain conformation. Relative to the
backbone (Figure 3a), the 5a O-Ag shows an increase in the prevalence of elongated helices (Figure 3g):
the dominant conformation (5a-1, 25%) is a right-handed helix with 3 RU per turn, in agreement with
an early helical model prediction [24]. This extended helical structure (pitch of 30 Å) has significant
flexibility—the helix encompasses just 25% of the simulation and frequently unwinds to extended chains
(5a-2 and 5a-4) as well as C-curve conformations (5a-3 and 5a-5) that are also present in the backbone
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(e.g., Y-4 and Y-5). Therefore, O-factor V has only a slight impact on the backbone conformation.
However, the glucose side chains (colored cyan in Figure 3g,h) are exposed for antibody binding.Vaccines 2020, 8, x 10 of 18 
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Serogroup 5b adds O-factor 7,8 (glucosylation on O-3 of rhamnose A) which, according to our
heuristic hypothesis, should have a similar effect as in serogroup 2, increasing the dominance of helices
in the 5b O-Ag conformations. This is in fact the case: although the 5b O-Ag has a similar dominant
Vaccines 2020, 8, 643 10 of 17
conformational family (Figure 3h, 5b-1, 24%) to 5a, the more minor C-curve conformations in 5a are
replaced with helices in 5b (5b-2, 13%; 5b-4, 7%). The chain also has a unique tight hairpin bend
conformation (5a-3, 11%) corresponding to the short r values adopted early in the 5b r time series
(Figure 2i).
In summary, conformational analysis suggest refinement of our proposed three broad heuristics
for the effects of substitution on the backbone conformation of the Shigella O-Ags, as follows. First,
substitution at rhamnose C (present in serogroups 2 and 3) restricts the O-Ag chain to predominantly
curved conformations, with a larger substituent (e.g., O-4 glucosylation in serogroup 2) having a
greater effect than a smaller one (e.g., O-2 O-acetylation in serotype 3). Second, additional substitution
on O-3 of rhamnose A (be it O-acetylation or glucosylation: 2a-3Ac, 2b, 3a, 5b) restricts the O-Ag to
helical conformations. Third, substitution at O-3 of rhamnose B (O-factor V, serogroup 5) has only a
slight effect on conformation, shifting the backbone to somewhat more extended O-Ag conformations.
To explain the origin of these general effects, we now investigate the impact of the substitutions on the
constituent glycosidic linkages in the S. flexneri O-Ag repeating unit.
3.4. O-Ag Glycosidic Linkage Conformations
As carbohydrate rings have fairly constrained chair conformations, chain flexibility in the S. flexneri
O-Ags arises principally from rotations about glycosidic linkages, which are commonly measured via
theϕ andψ dihedral angles. Ring substitutions can increase or, more commonly, decrease, the range of
motion for a glycosidic linkage. The range of motion for each of the glycosidic linkages in the serogroup
3 and 5 O-Ag RUs over the course of the simulations is shown in Figure 4 with scatter plot heatmaps
of the ϕ, ψ dihedral angle distribution over the course of the simulations. Fragments of the O-Ag
backbone showing the relative arrangements of the sidechains, the N-acetyl (blue) and the O-acetyl
(red) substituents for each of the serotypes are shown in Figure 5.
For the Y-backbone (Figure 4a), the ϕ dihedral for all linkages is restricted to a narrow range of
values around ϕ ≈ 40◦, whereas the ψ dihedral is more flexible with two primary conformations at ψ
≈ 10◦ and ψ ≈ −35◦ (hereafter referred to as +ψ and −ψ, respectively). The D-A linkage is the most
constrained, having the narrowest range for psi, because the close proximity of the N-acetyl group
to this β-D-GlcpNAc-(1→2)-α-L-RhapIII linkage restricts ψ rotations. The backbone dihedral angle
conformations are consistent with the scatter plots of theϕ,ψ linkages from short (60 ns) simulations of 3
RU chains [27]. Further, the estimates of key NOE distances (by r6 averaging) are in good agreement with
NMR NOE measurements for the native LPSs of serotype 3a [27] (Supplementary Materials Table S1)
and 5a [24] (Supplementary Materials Table S2), providing validation for our MD simulations [57].
Comparison of the heatmaps for substituted O-Ags with the backbone (serotype Y) maps allows a
closer identification of the specific effect of substitutions on the O-Ag local chain flexibility and dynamics.
For the first heuristic, we found that substitution at rhamnose C (serogroups 2 and 3) restricts
the extension of the O-Ag chain to predominantly curved conformations. Comparison of the ϕ,
ψ heatmaps for the Y backbone (Figure 4a) with those for serogroup 2 (Figure 4b–d) shows that the B-C
glycosidic linkage (α-L-RhapII-(1→3)-α-L-RhapI) is considerably restricted in serogroup 2 as compared
to the unsubstituted backbone. Serogroup 2 is glucosylated at O-4 of rhamnose C (O-factor II);
steric hindrance by this glucose side chain restricts the range of freedom in the neighboring ψ dihedral
of the α-(1→3) B-C linkage—see Figure 5a–c. Serogroup 3 (Figure 4e,f) shows a lesser restraint on
the B-C linkage, but the α-(1→3) C-D linkage is also restricted relative to the backbone. Serotype 3 is
O-2-acetylated on rhamnose C (O-factor 6), and the O-acetyl group is in close proximity to the N-acetyl
group of D (β-D-GlcpNAc), as shown in Figure 5d,e. Interactions with this neighboring N-acetyl
amplify the restrictive effect of the O-acetylation: the C-D linkage for serotype 3b is constrained with
partial access to −ψ conformations (mean ≈ −12◦) and glucosylation on rhamnose A (O-factor 7,8)
further limits the C-D linkage to +ψ orientations for serotype 3a (mean ≈ −6◦). It is interesting that a
similar restriction in either of these α-L-Rhap-(1→3) linkages (B-C and C-D) to −ψ angles has a similar
conformational effect for the serogroup 2 and 3 O-Ags, reducing the extension of the O-Ag chain.
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In contrast, the serogroup 5 O-Ag B-C linkages remain unconstrained, adopting predominantly +ψ
orientations (mean ≈ 7◦) that result in a greater prevalence of extended structures despite glucosylation
on O-3 of rhamnose B (O-factor V). This accounts for the more extended helical conformation in
our molecular dynamics simulations as compared to the static model which was built with −ψ B-C
orientations [24].Vaccines 2020, 8, x 12 of 18 
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In contrast, the α-L-RhapIII-(1→2)-α-L-RhapII linkage (A-B) is flexible across all serogroup 2, 3,
and 5 O-Ags (Figure 4, first column), significantly contributing to the conformational flexibility of
the O-Ags. For serogroup 2, the linkage shifts to favor –ψ orientations (increasing the prevalence of
C-curve conformations) while the serogroup 3 A-B linkages remain largely unchanged compared to
the backbone (serotype Y). Inspection of the backbone fragments in Figure 5 shows that the glucose
substituent on O-4 of rhamnose C is in closer proximity to the A-B linkage than the less bulky O-acetyl
substituent at the O-2 position. For serogroup 5, the adjacent glucose side-chain on O-3 of rhamnose B
does impose a small steric hindrance to the A-B linkage, possibly contributing to extension of the O-Ag
chains in this serogroup.
For our second heuristic, we found that further substitution on O-3 of rhamnose A shifts the O-Ag
to extended helical conformations. Comparison of the heatmaps for 2b (Figure 4d), 3a (Figure 4e),
and 5b (Figure 4h) with the serotype Y backbone shows that glucosylation at this position (O-factor 7,8)
significantly reduces the range of motion for the ψ dihedral of the D-A β-D-GlcpNAc-(1→2)-α-L-RhapI
linkage from two dominant conformations at ψ ≈ 15◦ (+ψ) and ψ ≈ −45◦ (−ψ) to a single dominant
conformation atψ≈ 12◦. In combination with−ψ orientations for the A-B and B-C linkages, this induces
a primary helical conformation for serotype 3a. The glucose side-chain (residue F) is in close proximity
to the N-acetyl group of the adjacent D residue (β-D-GlcpNAc), as shown in Figure 5c,d. Steric clashes
between the glucose substituent and the N-acetyl group hinders rotation around the D-A linkage and
reduces chain flexibility. The α-D-Glcp-(1→3)-α-L-RhapIII side chain (F-A, Figure 4, fifth column) is in
turn also restricted by the N-acetyl moiety with a single conformation at ϕ, ψ ≈ −52◦, −36◦, which is in
agreement with NMR measurements for short serotype 3a fragments that predict a −ψ orientation [31].
O-acetylation at this position (O-factor 9, serotype 2a-3Ac, Figure 4c) has a lesser, but similar,
restriction on the range of rotation. Steric clashes between these two groups explain the large
conformational restriction produced by glucosylation (serotypes 2b and 3a) as well as O-acetylation
(2a-3Ac, Figure 5b) on rhamnose A. The conformational effects of this restraint are to increase the
incidence of more regular helical structures in these serotypes.
Finally, for the third heuristic, we found that substitution at O-3 of rhamnose B (O-factor V,
serogroup 5) has only a slight effect on conformation, shifting the backbone to somewhat more
extended O-Ag conformations. Comparison of the heatmaps for serogroup 5a (Figure 4g) with the
backbone shows that glucosylation at this position has little effect on the backbone A-B and B-C
linkages: the glucose side chains do not interfere with rotations about the bonds (Figure 5f,g).
4. Discussion
Our simulations show that S. flexneri serogroups 2, 3, and 5 all have very flexible O-Ags. However,
substitutions of the backbone residues limit the range and distribution of chain conformations in
different ways. Our analysis has suggested three broad heuristics for the effects of substitution on
the backbone conformation of the Shigella O-Ags: (1) substitution on rhamnose C has the greatest
impact on restricting the extension and conformational range of the O-Ags; (2) substitution at O-3
of rhamnose A (2a-3Ac, 2b, 3a, 5b) also has a strong impact, restricting the O-Ags to predominantly
helical conformations; (3) substitution at O-3 of rhamnose B (serogroup 5) has only a slight effect
on conformation.
Can this conformational analysis give some insight into whether a quadrivalent vaccine containing
S. flexneri serotypes 2a, 3a (as well as 6 and S. sonnei) could provide broad coverage against S. flexneri
serotypes 3b, 5a, and 5b? The factors that lead to cross-protection between O-Ags are not well
understood. However, an assumption that similar O-Ag conformations is a necessary (if not
sufficient) criterion for cross-protection between O-Ags seems reasonable. However, immunodominant
substitutions that change the binding surface (but perhaps not the conformation) may be confounding
factors. On a conformational basis, we postulate that the two substitutions that produce the greatest
conformational effects should be represented in the vaccine serotypes. Therefore, the vaccine should
contain serotypes with substitutions on rhamnose C (O-factors II and 6) as well as rhamnose A
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(O-factors 9 and 7,8). Inclusion of an additional serotype with substitution at rhamnose B (O-factor V)
seems less likely to be necessary. On the basis of this argument, the 2a-3Ac serotype containing both
O-factors II and 9 would seem to be sufficient, whereas 2a (only substituted on rhamnose C) would not.
Cross-protection within serogroup 2 (2a-3Ac and 2b) seems likely due to the similar helical
conformations of the serotypes within the group, and cross-protection with the helices in serogroup 3
and serogroup 5 may be possible. However, this conformational argument does not consider serogroup
3′s immunodominant O-2-acetylation on rhamnose C (O-factor 6) [31,32], which is a strong basis for
including this serotype. Further reasons to include 3a are the prevalence of 3a infection, the lack of
expected cross-protection from 2a [58–60], and potential cross-protection by 3a against 2b arising from
the shared glucosylation of rhamnose A (O-factor 7,8). Although serotype 3b is conformationally more
similar to the non-acetylated 2a chain, the minor C-curve and helical conformations of 3b may allow
for partial cross-reactivity from a 2a-3Ac vaccine component. Further, serotypes 3a and 3b share minor
conformational families, which may be sufficient to elicit cross-reactivity. Furthermore, serogroup
3a may provide cross-reactivity with other disease-causing serogroups: serotypes 1b and 4b express
O-factor 6 and serotype X expresses O-factor 7,8.
Finally, on the basis of conformational similarity, we suggest that the inclusion of serogroup 5 is
not necessary in the vaccine, as serotype 5a shares similar helical structures with the 2a-3Ac chain.
Further, the partial O-acetylation on O-3 of rhamnose A (O-factor 9) for serotype 5a could provide
cross-reactivity with an O-acetylated serotype 2a vaccine, although the exposure of the O-factor V
glucosylation for antibody binding may be a confounding factor. In future work, we will investigate
the O-Ags of the next most prevalent serogroups identified by the GEMS report—serogroups 6 and
1—to allow for further development of our heuristics for the conformations of the S. flexneri O-antigens.
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serotype 5a 1H distances to NMR measurements and previous MD study.
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